NCT04414514View on ClinicalTrials.gov

Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

PHASE2RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

January 31, 2028

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

Ruxolitinib 1.5% Cream

Topical Ruxolitinib 1.5% Cream

Trial Locations (1)

17033

RECRUITING

Penn State Hershey Medical Center, Hershey

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

Milton S. Hershey Medical Center

OTHER